- Available:In stock528
- Availability date:2020-07-30
- Dosage form:Bottle
- In stock:528 Items
Zineryt is an erythromycin-zinc complex that has anti-inflammatory, antimicrobial and comedonolytic effects. erythromycin bacteriostatically affects the microorganisms that cause acne: propionibacteria acnes and streptococcus epidermidis. zinc reduces the secretion of the sebaceous glands, has an astringent effect.
Pharmacokinetics The complex relationship of the components of the drug provides better penetration into the skin of active substances. Zinc is mainly associated with follicular epithelium and is not absorbed into the systemic circulation. An insignificant part of erythromycin undergoes a systemic distribution and is subsequently excreted.
Starting treatment, the liquid from the solvent bottle must be poured into the powder bottle. after this, the vial should be shaken until the powder has dissolved, and then close the lid with the applicator, which is attached.
Instructions for the preparation of rr Zineryt
1. The package contains 2 bottles (bottle A and B) and 1 applicator.
Open the caps on both bottles. Save the cap from vial A that contains the powder.
2. Pour solvent from vial B into vial A, which contains the powder. Empty bottle B can be thrown away.
3. Close vial A, which contains the powder and solvent, using the cap that was left.
4. Shake vial A for 1 min.
5. Remove the cap from bottle A and fit the applicator.
6. Push the cap that contains the applicator into a full bottle and close it tightly.
7. Open the bottle cap and check if the applicator holds firmly. If necessary, firmly press the applicator.
8. The solution remains stable for 5 weeks after preparation. Indicate the expiration date on the bottle.
Zineryt should be applied in a thin layer on the skin of the face or on the affected areas (not only on the affected area itself) until the entire area that needs to be treated is covered (about 0.5 ml of the drug should be used each time).
Application of the Zineryt preparation is carried out by tilting the bottle with the applicator down so that the applicator is opposite the skin, and rubbing the skin with the applicator with light pressure. The amount of Zenerit is controlled by pressure.
Dosage Zineryt is used 2 times a day, as a rule, for 10-12 weeks. A tangible therapeutic effect is usually achieved within the first 12 weeks. If during this period no tangible improvement is achieved or even deterioration is observed, the patient should consult a doctor for examination regarding the presence of resistance of the bacterial microflora. If resistance to bacterial microflora has arisen, the use of the drug should be discontinued for 2 months.
Zinerytis is contraindicated in patients with hypersensitivity to erythromycin or other macrolide antibiotics or to zinc, di-isopropyl sebacate, ethanol.
Characterization of organ systems infrequently (1/1000, 1/100) very rare (1/10 000), unknown (cannot be established from the available data) from the immune system hypersensitivity (symptoms may include a rash, angioedema, itching, swelling of the mouth, face, lips or tongue, and shortness of breath) on the part of the skin and subcutaneous tissue itching erythema* skin irritation* burning sensation * dry skin skin peeling
* Erythema, skin irritation, and a burning sensation of the skin are temporary and minor clinical signs.
Zineryt is intended solely for the treatment of skin, it is necessary to avoid contact with the eyes and the mucous membrane of the nose and oral cavity.
Cross-resistance can occur when used with other macrolide antibiotics, as well as lincomycin and clindamycin.Cross-resistance can be between macrolides.
Use during pregnancy and lactation
Pregnancy. The data obtained when using the drug during pregnancy do not show the damaging effects of erythromycin on pregnancy or the baby. Erythromycin can be used during pregnancy.
Lactation. Only a small amount of erythromycin passes into breast milk, so it can be used during lactation.
Fertility. Fertility data show nothing special.
Children. The drug is used in children aged 12 years in connection with clinical trials in children who have reached puberty.
The ability to influence the reaction rate when driving vehicles or working with other mechanisms. There is no evidence regarding the effect of Zineryt on the ability to drive vehicles or work with other mechanisms. However, any influence is unlikely.